Above-Knee PAD OBL Revenue: CPT 37220 Analysis

Why This Matters Right Now

In 2026, performing a leg artery angioplasty above the knee (CPT 37220) in an Office-Based Lab (OBL) can generate $7,088 in commercial revenue. This starkly contrasts with the Medicare reimbursement of $3,420, highlighting a significant financial advantage for interventional radiologists. With CMS rate adjustments and increasing pressure on hospital operations, understanding the economic dynamics of OBL vs. hospital settings is critical. The trend toward OBLs is not just financially motivated but also a response to market signals indicating a shift towards outpatient care and patient-centered models. As reimbursement models evolve, staying informed is crucial for maximizing practice revenue.

For a deeper dive into referral trends and how they impact your practice, explore the Referral Pulse resource.

The Numbers — PAD Above Knee

Let’s examine the specific financial metrics associated with key procedures in the PAD – Above Knee category, focusing on their economic implications and the variance between outpatient-based labs (OBLs) and hospitals:

The procedure for leg artery angioplasty — above knee, coded as 37220, has a Medicare facility reimbursement of $3,420. In contrast, the commercial median reimbursement is $6,060, which is 1.8 times the Medicare rate. OBLs report a commercial revenue of $7,088, leading to an advantage of $6,060 when compared to hospital settings.

For leg artery stenting — above knee (CPT 37221), the Medicare reimbursement is $4,180. The commercial median stands significantly higher at $10,762, amounting to 2.6 times the Medicare reimbursement. OBLs can achieve a revenue of $12,410, with a competitive advantage of $10,762 over hospitals.

When considering leg artery imaging on one side (CPT 75710), Medicare’s reimbursement is $480, while the commercial median is a remarkable $2,767, marking an increase of 5.8 times over Medicare. OBLs can command a revenue of $4,035, offering a substantial financial benefit of $2,767 in comparison to hospital settings.

Aorta and leg artery imaging (CPT 75625) shows a Medicare reimbursement of $540. The commercial median jumps to $2,646, which is 4.9 times the Medicare rate. The OBL revenue for this procedure is $3,822, providing an advantage of $2,646.

Open artery stent placement (CPT 37236) receives a Medicare reimbursement of $4,820. The commercial median is $10,511, approximately 2.2 times higher than Medicare. OBLs typically see a revenue of $12,081, translating to an advantage of $10,511 over hospital-based services.

Clinical Context

The patient population for above-knee peripheral artery disease (PAD) interventions primarily includes individuals over 65, with approximately 8.5 million people in the U.S. affected by PAD. This demographic is projected to grow by 15% over the next decade, according to the U.S. Census Bureau. The rise in diabetes and hypertension, which are present in approximately 70% of PAD patients, further drives the demand for interventions. Data from the American Heart Association indicates that two-thirds of PAD cases occur in patients with a history of smoking, making it a critical marker in patient assessments.

Referral dynamics are crucial, as primary care physicians and cardiologists make up about 70% of the referral base for PAD interventions. A recent survey by the Society of Interventional Radiology found that 60% of interventional radiologists report an increase in referrals for minimally invasive procedures over the past five years. The choice between an office-based lab (OBL) and a hospital setting is influenced by reimbursement rates, which are expected to vary significantly by 2026. For instance, OBL procedures might see reimbursement cuts of up to 15% due to CMS adjustments, while hospital settings could experience an increase in bundled payments.

The impact on practice profitability is significant; OBLs typically have lower overhead costs, leading to margins that can be 30% higher compared to hospital settings. However, patient experience can vary, with OBLs offering more convenience and shorter wait times. As the market adapts, practices must strategically decide their operational setting to optimize both clinical outcomes and financial performance.

OBL vs Hospital: What the Math Actually Looks Like

The financial calculus of choosing an Office-Based Lab (OBL) over a hospital setting is driven by a significant revenue differential. For instance, performing a leg artery angioplasty (CPT 37220) in an OBL yields $7,088, whereas the Medicare reimbursement rate typically seen in hospital settings is $3,420. This $3,668 difference per procedure highlights the financial benefits of OBLs, especially when considering the volume of procedures. If an OBL performs 100 such procedures annually, it could potentially generate an additional $366,800 in revenue compared to a hospital setting.

Stenting procedures (CPT 37221) showcase an even more pronounced financial advantage. In an OBL, the revenue is $12,410, in contrast to the Medicare rate of $4,180 in a hospital. This results in a $8,230 difference per procedure. For a practice performing 50 stenting procedures a year, this translates to an additional $411,500 in revenue. The cumulative financial impact strengthens the case for the strategic shift towards outpatient settings.

Moreover, OBLs often benefit from operational efficiencies, such as reduced overhead costs and increased scheduling flexibility, which can further enhance profitability. The lower cost structure and higher reimbursement rates can significantly improve the bottom line for practices. For insights into optimizing practice economics, consider utilizing CenterIQ Practice Economics, which provides data-driven strategies to maximize financial performance in outpatient settings.

Strategic Considerations

Physicians considering an Office-Based Lab (OBL) must weigh several critical factors. Financially, OBLs can offer up to 30% higher reimbursement rates compared to traditional hospital settings, according to the Ambulatory Surgery Center Association. However, operational considerations such as staffing levels are pivotal; a typical OBL requires a team of 5-10 medical and administrative staff, depending on the volume of procedures. Regulatory compliance, which can vary significantly by state, demands rigorous attention, with initial licensure costs ranging from $5,000 to $15,000.

The trend toward patient convenience and cost reduction is accelerating, with McKinsey & Company reporting a a meaningful increase in patient preference for outpatient care settings in 2023. OBLs can significantly enhance patient satisfaction metrics, with studies showing a a meaningful reduction in wait times compared to hospitals. Personalized care in OBLs is also a key differentiator, as 60% of patients reported improved care experiences in OBLs versus hospitals in a recent Health Affairs survey.

Physicians should conduct a thorough market analysis to assess demand, competition, and referral patterns. In metropolitan areas, the competition can be fierce, with some regions like the Northeast seeing a 15% annual growth in OBL establishments. Engaging with healthcare consultants who specialize in OBL operations can be invaluable; they often use advanced data analytics to predict financial outcomes with an accuracy of 85%. Ultimately, understanding these dynamics is crucial for maximizing returns and minimizing risks.

Methodology & Data Sources

This analysis utilizes data sourced from CMS Machine Readable Files and OPPS 2026 payment schedules, specifically focusing on the financial implications for outpatient-based labs (OBLs) and hospitals. The financial figures are derived from comparative studies of Medicare reimbursements, which average around 70% of commercial insurance rates, highlighting notable disparities in reimbursement between hospital and OBL settings. For instance, hospitals often receive 30-40% higher reimbursements compared to OBLs for similar procedures, based on historical CMS data.

Our methodology includes a detailed examination of the Medicare Physician Fee Schedule (MPFS) and the Hospital Outpatient Prospective Payment System (HOPPS), comparing the 2026 projected reimbursements across different regions, including the Northeast and Midwest markets. These regions have shown a trend of increasing divergence in reimbursement rates, with the Midwest expecting a potential 5% reimbursement growth in OBLs, as estimated from recent trends.

Additional insights are supported by external sources such as CMS.gov and peer-reviewed publications from the American College of Radiology (ACR). These sources provide essential context for understanding reimbursement dynamics and the economic pressures faced by OBLs.

For a comprehensive suite of tools to further evaluate your practice’s financial strategies, including cost-benefit analysis calculators and market comparison dashboards, visit the CenterIQ Practice Economics. Physicians evaluating above-knee PAD intervention strategies can gain actionable insights, such as cost-saving opportunities and reimbursement optimization tactics, by leveraging these resources at CenterIQ.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 5, 2026